我从酪氨酸磷酸化抑制剂到靶向免疫治疗的历程，作为对抗癌症的策略。
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
机构信息
Unit of Cellular Signaling, Department of Biological Chemistry, Silberman Life Sciences Institute, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel
Unit of Cellular Signaling, Department of Biological Chemistry, Silberman Life Sciences Institute, The Hebrew University of Jerusalem, 91904 Jerusalem, Israel.
出版信息
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11579-11586. doi: 10.1073/pnas.1816012116. Epub 2019 May 10.
Abstract
Since the 1980s there has been a drive toward personalized targeted therapy for cancer. "Targeted cancer therapy" originally focused on inhibiting essential tumor survival factors, primarily protein tyrosine kinases. The complexity and rapid mutability of tumors, however, enable them to develop resistance to tyrosine kinase inhibitors (TKIs), even when these are multitargeted or applied in combination. This has led to the development of targeted cancer immunotherapy, to enhance immune surveillance against the tumor. In this paper, we provide a personal view of the development of targeted therapy, from TKIs to targeted immunotherapy.
摘要
自 20 世纪 80 年代以来，人们一直在努力为癌症提供个性化的靶向治疗。“靶向癌症治疗”最初侧重于抑制肿瘤生存的基本因素，主要是蛋白酪氨酸激酶。然而，肿瘤的复杂性和快速突变能力使它们能够对酪氨酸激酶抑制剂（TKI）产生耐药性，即使这些抑制剂是多靶点的或联合应用的。这导致了靶向癌症免疫疗法的发展，以增强对肿瘤的免疫监视。在本文中，我们从 TKI 到靶向免疫疗法，提供了对靶向治疗发展的个人观点。
相似文献
1
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.我从酪氨酸磷酸化抑制剂到靶向免疫治疗的历程，作为对抗癌症的策略。
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11579-11586. doi: 10.1073/pnas.1816012116. Epub 2019 May 10.
2
Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.使用小分子抑制剂靶向非受体酪氨酸激酶：近期进展综述
J Drug Target. 2016;24(3):192-211. doi: 10.3109/1061186X.2015.1068319. Epub 2015 Jul 27.
3
[Protein tyrosine kinase inhibitors in cancer therapy].[蛋白酪氨酸激酶抑制剂在癌症治疗中的应用]
Pathol Biol (Paris). 2012 Aug;60(4):229-33. doi: 10.1016/j.patbio.2012.05.007. Epub 2012 Jun 26.
4
Novel approaches to the development of tyrosine kinase inhibitors and their role in the fight against cancer.新型酪氨酸激酶抑制剂的开发及其在抗癌中的作用。
Expert Opin Drug Discov. 2014 Jan;9(1):77-92. doi: 10.1517/17460441.2014.865012. Epub 2013 Dec 3.
5
Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020).过去 20 年（2001-2020 年）用于实体瘤的酪氨酸激酶抑制剂。
J Hematol Oncol. 2020 Oct 27;13(1):143. doi: 10.1186/s13045-020-00977-0.
6
The molecular basis for RET tyrosine-kinase inhibitors in thyroid cancer.RET酪氨酸激酶抑制剂在甲状腺癌中的分子基础。
Best Pract Res Clin Endocrinol Metab. 2017 Jun;31(3):307-318. doi: 10.1016/j.beem.2017.04.013. Epub 2017 May 10.
7
Receptor tyrosine kinases and targeted cancer therapeutics.受体酪氨酸激酶与靶向癌症治疗药物。
Biol Pharm Bull. 2011;34(12):1774-80. doi: 10.1248/bpb.34.1774.
8
Nanoformulations of small molecule protein tyrosine kinases inhibitors potentiate targeted cancer therapy.小分子蛋白酪氨酸激酶抑制剂的纳米制剂增强了靶向癌症治疗。
Int J Pharm. 2020 Jan 5;573:118785. doi: 10.1016/j.ijpharm.2019.118785. Epub 2019 Oct 31.
9
Role of tyrosine kinase inhibitors in cancer therapy.酪氨酸激酶抑制剂在癌症治疗中的作用。
J Pharmacol Exp Ther. 2005 Dec;315(3):971-9. doi: 10.1124/jpet.105.084145. Epub 2005 Jul 7.
10
Foreword. Target therapy for cancer: anti-cancer drugs targeting growth-factor signaling molecules.前言。癌症的靶向治疗：针对生长因子信号分子的抗癌药物。
Biol Pharm Bull. 2011;34(12):1773. doi: 10.1248/bpb.34.1773.
引用本文的文献
1
New Kinase Inhibitors That Are Selectively Cytotoxic for Tumor Cells.对肿瘤细胞具有选择性细胞毒性的新型激酶抑制剂。
Dokl Biochem Biophys. 2025 Apr;521(1):239-245. doi: 10.1134/S1607672924601446. Epub 2025 Apr 12.
2
Breaking the Invisible Barriers: Unleashing the Full Potential of Immune Checkpoint Inhibitors in Oncogene-Driven Lung Adenocarcinoma.突破无形障碍：释放免疫检查点抑制剂在癌基因驱动的肺腺癌中的全部潜力。
Cancers (Basel). 2023 May 13;15(10):2749. doi: 10.3390/cancers15102749.
3
"Pharmacogenetics of Cancer" - special issue.《癌症的药物遗传学》——特刊
Cancer Drug Resist. 2020 Feb 20;3(2):225-231. doi: 10.20517/cdr.2020.10. eCollection 2020.
4
Fluorescence Lifetime Imaging Probes for Cell-Based Measurements of Enzyme Activity.用于基于细胞的酶活性测量的荧光寿命成像探针。
Methods Mol Biol. 2022;2394:133-162. doi: 10.1007/978-1-0716-1811-0_9.
5
Magnolol and Honokiol Inhibited the Function and Expression of BCRP with Mechanism Exploration.厚朴酚和和厚朴酚通过作用机制探讨抑制 BCRP 的功能和表达。
Molecules. 2021 Dec 6;26(23):7390. doi: 10.3390/molecules26237390.
6
From Toxicity to Selectivity: Coculture of the Fluorescent Tumor and Non-Tumor Lung Cells and High-Throughput Screening of Anticancer Compounds.从毒性到选择性：荧光肿瘤与非肿瘤肺细胞的共培养及抗癌化合物的高通量筛选
Front Pharmacol. 2021 Oct 11;12:713103. doi: 10.3389/fphar.2021.713103. eCollection 2021.
7
Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.确定天然多酚儿茶素作为一种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的多靶点药物用于新型冠状病毒肺炎（COVID-19）的合理治疗：一种综合计算方法。
Brief Bioinform. 2021 Mar 22;22(2):1346-1360. doi: 10.1093/bib/bbaa378.
8
RIG-1-Like Receptor Activation Synergizes With Intratumoral Alpha Radiation to Induce Pancreatic Tumor Rejection, Triple-Negative Breast Metastases Clearance, and Antitumor Immune Memory in Mice.视黄酸诱导基因I样受体激活与瘤内α辐射协同作用，可诱导小鼠胰腺肿瘤消退、清除三阴性乳腺癌转移灶并产生抗肿瘤免疫记忆。
Front Oncol. 2020 Jul 17;10:990. doi: 10.3389/fonc.2020.00990. eCollection 2020.
9
QnAs with Alexander Levitzki.与亚历山大·列维茨基的问答
Proc Natl Acad Sci U S A. 2019 Jun 11;116(24):11562-11563. doi: 10.1073/pnas.1906350116. Epub 2019 May 6.
本文引用的文献
1
Tumour heterogeneity and metastasis at single-cell resolution.单细胞分辨率下的肿瘤异质性和转移。
Nat Cell Biol. 2018 Dec;20(12):1349-1360. doi: 10.1038/s41556-018-0236-7. Epub 2018 Nov 26.
2
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma.定义与黑色素瘤免疫检查点治疗应答相关的 T 细胞状态。
Cell. 2018 Nov 1;175(4):998-1013.e20. doi: 10.1016/j.cell.2018.10.038.
3
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.肿瘤细胞程序性死亡配体 1 表达促进 T 细胞排除和对检查点阻断的抵抗
Cell. 2018 Nov 1;175(4):984-997.e24. doi: 10.1016/j.cell.2018.09.006.
4
Recent Advances in the Clinical Development of Immune Checkpoint Blockade Therapy for Mismatch Repair Proficient (pMMR)/non-MSI-H Metastatic Colorectal Cancer.免疫检查点阻断疗法在错配修复 proficient（pMMR）/非微卫星高度不稳定转移性结直肠癌临床开发方面的最新进展
Clin Colorectal Cancer. 2018 Dec;17(4):258-273. doi: 10.1016/j.clcc.2018.06.004. Epub 2018 Jun 21.
5
Recurrent Glioblastoma Treated with Recombinant Poliovirus.复发性神经胶质瘤的重组脊髓灰质炎病毒治疗。
N Engl J Med. 2018 Jul 12;379(2):150-161. doi: 10.1056/NEJMoa1716435. Epub 2018 Jun 26.
6
Mechanisms of Intrinsic Tumor Resistance to Immunotherapy.内在肿瘤对免疫疗法的抵抗机制。
Int J Mol Sci. 2018 May 2;19(5):1340. doi: 10.3390/ijms19051340.
7
Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.酪氨酸激酶抑制剂在慢性期 CML 治疗中的应用：一线决策策略。
Curr Hematol Malig Rep. 2018 Jun;13(3):202-211. doi: 10.1007/s11899-018-0449-7.
8
T cell-induced CSF1 promotes melanoma resistance to PD1 blockade.T 细胞诱导 CSF1 促进黑色素瘤对 PD1 阻断的耐药性。
Sci Transl Med. 2018 Apr 11;10(436). doi: 10.1126/scitranslmed.aan3311.
9
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
10
Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies.联合免疫检查点阻断的癌症治疗：机制与策略。
Immunity. 2018 Mar 20;48(3):417-433. doi: 10.1016/j.immuni.2018.03.007.
Zotero 插件